In different subtypes of MAFLD, in comparison to healthy controls, the chemerin levels of NAFL patients were higher, whereas, there was no obvious difference in chemerin levels between NASH patients and controls. This evidence concerns the gene RARRES2 and metabolic dysfunction-associated steatohepatitis.